









Markets
/
Stocks
/
nasdaq-lpcn
/

Lipocine Inc

LPCN

2.880USD

+0.030+1.05%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

15.48MMarket Cap

LossP/E TTM



Lipocine Inc

2.880

+0.030+1.05%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

158 / 506

Overall Ranking

269 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

7.375

Target Price

+162.46%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 2139.63% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 11.20M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 8.35K.%!(EXTRA int=2)

Fairly Valued

The company’s latest PE is -3.42, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 680.47K shares, decreasing 5.75% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 224.88K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.46.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.69, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 622.85K, representing a year-over-year increase of 595.42%, while its net profit experienced a year-over-year increase of 28.12%.

Score

Industry at a Glance

Previous score

7.69

Change



Financials

8.92

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.54

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

9.25

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.56

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.18

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -3.33, which is -61.92% below the recent high of -1.27 and -2.45% above the recent low of -3.42.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 158/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Lipocine Inc is 7.38, with a high of 8.00 and a low of 6.75.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

7.375

Target Price

+156.08%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Lipocine Inc

LPCN

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.24, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 3.03 and the support level at 2.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.24

Change

0.24

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.003

Sell

RSI(14)

43.661

Neutral

STOCH(KDJ)(9,3,3)

19.269

Neutral

ATR(14)

0.113

Low Volatility

CCI(14)

-56.576

Neutral

Williams %R

74.425

Sell

TRIX(12,20)

-0.214

Sell

StochRSI(14)

58.881

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.892

Sell

MA10

2.915

Sell

MA20

2.943

Sell

MA50

3.056

Sell

MA100

3.176

Sell

MA200

3.558

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 12.56%, representing a quarter-over-quarter decrease of 0.99%. The largest institutional shareholder is The Vanguard, holding a total of 224.88K shares, representing 4.15% of shares outstanding, with 0.21% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

226.28K

+2.18%

Patel (Mahesh V)

109.05K

+1.52%

BlackRock Institutional Trust Company, N.A.

89.27K

Geode Capital Management, L.L.C.

58.83K

+2.38%

Susquehanna International Group, LLP

38.98K

+55.89%

Higuchi (John W)

40.80K

Renaissance Technologies LLC

Star Investors

37.51K

+4.10%

Dimensional Fund Advisors, L.P.

24.93K

+21.54%

State Street Global Advisors (US)

18.63K

Northern Trust Investments, Inc.

13.16K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.22, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.29. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.